Previous Article | Next Article ![]()
Journal of Virology, May 2005, p. 6134-6141, Vol. 79, No. 10
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.10.6134-6141.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Sarah T. Gross,2,
Mark E. Girvin,1 and
Duncan W. Wilson2*
Department of Biochemistry,1 Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, New York 104612
Received 16 July 2004/ Accepted 14 January 2005
|
|
|---|
|
|
|---|
Several studies have indicated that viral envelopment and tegumentation occur at late Golgi or post-Golgi compartments, such as the trans-Golgi network and endosomes (4, 6, 15, 16, 23, 25, 31, 33). However, the molecular details that drive envelopment are still poorly understood. It is thought that a network of interactions among viral glycoproteins present in the host organelle membranes, tegument proteins, and capsid proteins is critical for this process. In this model, tegument proteins serve as a bridge, binding to the cytoplasmic tails of viral glycoproteins, each other, and capsid proteins, thus recruiting capsids to the site of envelopment and allowing capsids to bud into organelles. In support of this hypothesis, several interactions were recently shown or suggested among various tegument proteins (9, 10, 20, 22, 32), between the tegument and glycoproteins (12, 36), and between the capsid and the tegument (24, 35).
It appears that the web of interactions among the tegument and glycoproteins is very redundant. For example, VP16 is known to interact with VP22 (10) and Vhs (29, 32) as well as gH (13, 36) and possibly gD and gB (36). Also, in pseudorabies virus, tegument protein VP22 binds to both gM and gE (12), and simultaneous deletion of both glycoproteins is required to abrogate envelopment and prevent incorporation of VP22 into mature viral particles (3). In HSV, simultaneous deletion of several glycoprotein tails, such as gE, gI, and gD, is required in order to appreciably affect viral egress and inhibit viral maturation and envelopment (5, 11).
Previous work from our laboratory showed that VP16 interacts with the cytoplasmic tail of gH both in vitro and in vivo (13). In these experiments, VP16 could be specifically recovered from infected cell extracts by using a glutathione S-transferase-gH tail fusion protein. Additionally, in cells transfected with a construct expressing green fluorescent protein (GFP) fused to the gH tail and infected with wild-type HSV, anti-GFP antibodies could be used to coimmunoprecipitate VP16. These experiments also revealed that the interaction between VP16 and the gH carboxy terminus is temperature dependent, in that binding took place only at the physiological temperature and not at lower temperatures. Alanine scanning mutagenesis of the gH tail revealed that replacing a single proline residue at the center of the tail with an alanine stimulated the binding of VP16 to gH at 37°C and also relieved the temperature constraints of binding, allowing gH to interact with VP16 even at 4°C (13).
Here we report that virally expressed gH and VP16 can be coimmunoprecipitated from HSV-infected cells, confirming our previous in vitro and in vivo data. As was found in our earlier studies, this interaction is strikingly temperature dependent, occurring only at 37°C. Furthermore, two-dimensional (2D) nuclear magnetic resonance (NMR) analyses of synthetic peptides with the sequence of the gH cytoplasmic tail reveal that the temperature dependence of binding can be explained by conformational changes in the tail. We propose that the gH tail has evolved to be unstructured at a physiologically relevant temperature in order to interact with multiple possible tegument partners during HSV assembly.
|
|
|---|
Antibodies. Anti-VP16 monoclonal antibody 14-5 and goat anti-VP16 polyclonal antibody v-20 were obtained from Santa Cruz Biotechnology. Rabbit anti-goat antibody (A-5420) and goat anti-rabbit immunoglobulin G (A-6154) were obtained from Sigma.
Coimmunoprecipitation of full-length gH and VP16. Cells were infected with HSV-1 strain SC16 or SCgHZ at a multiplicity of 10 or left uninfected. At 18 h postinfection, postnuclear supernatants (PNS) were prepared as previously described (15). Lysis buffer was added to each sample of PNS to final concentrations of 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.5% NP-40, 0.5% EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 5 µg/ml of leupeptin, 5 µg/ml antipain, 2 mM dithiothreitol, and 200 µg/ml of bovine serum albumin, and the mixtures were incubated for 30 min on ice. The resulting lysates were centrifuged for 15 min at 15,000 x g and precleared by incubation with prewashed protein G-agarose beads for 20 min at the temperature subsequently used for immunoprecipitation. After the beads were pelleted for 20 s at 15,000 x g, the supernatants were collected and mixed with new protein G beads that had been preincubated with mouse anti-VP16 monoclonal antibody for 1 h at 4°C. Incubation was performed for 30 min at the appropriate temperature. After the beads were washed five times with lysis buffer, bead-bound and unbound materials were subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and Western blotted with goat anti-VP16 and rabbit anti-gH antibodies as previously described (13).
Synthesis of peptides with the sequences of the wild-type and proline-to-alanine mutant gH tails. The sequences of the synthesized peptides were KVLRTSVPFFWRRE, corresponding to the wild-type gH cytoplasmic tail, and KVLRTSVAFFWRRE, corresponding to the proline-to-alanine (PA) mutant tail (13). Peptides were synthesized on a 0.1-mmol scale by solid-phase peptide synthesis with an ABI433A peptide synthesizer and a standard protocol (9-fluorenylmethoxy carbonyl chemistry). Preloaded resin reagents piperidine, diisopropylethylamine, N-methylpyrrolidone, dichloromethane, and 9-fluorenylmethoxy carbonyl amino acids and an hydroxybenzotriazole activation kit were purchased from Applied Biosystems. Peptide resins were cleaved and deprotected by using a mixture of trifluoroacetic acid, thioamisole, ethanedithiol, phenol, and water for 2 h. Peptides were precipitated with ether and washed.
Peptides were characterized by matrix-assisted laser desorption ionization-time-of-flight mass spectroscopy with a Perspective Biosystems Voyager DE as well as by analytical high-pressure liquid chromatography (HPLC) with a C8 reverse-phase column (2.1 by 250 mm) on a Hewlett-Packard HPLC 1090 instrument. Amino acid analysis was performed with a Hewlett-Packard Amino Quant HPLC system. Peptides were purified by HPLC with 1-cm C18 reverse-phase columns and dissolved in phosphate buffer to final concentrations of 2.7 mM peptide in 15 mM phosphate buffer at pH 6.1 (for the wild-type gH tail peptide) and 0.14 mM peptide in 20 mM phosphate buffer at pH 6.0 (for the PA mutant gH tail peptide).
NMR spectroscopy of wild-type and mutant gH peptides. All NMR spectra were recorded at 600 MHz on a Bruker DRX600 spectrometer. 1H chemical shifts were referenced to an internal 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid standard at 0 ppm. Standard methods were used to obtain homonuclear DQF-COSY (30), TOCSY (2, 27), and NOESY (17) spectra for wild-type gH and PA peptides at 10°C and 37°C in 90% H2O and 10% D2O. The TOCSY spectra were acquired with spin-lock periods of 42 and 100 ms, and the NOESY spectra were obtained with 300-ms mixing times. For all 2D spectra, 32 scans were collected. The spectra were acquired with 4,096 complex data points in the direct dimension and 680 points in the indirect dimension, with a spectral width of 14 ppm (8,389 Hz) in both dimensions.
The one-dimensional (1D) spectra of the wild-type gH and PA peptides were collected at a series of temperatures ranging from 2 to 45°C in approximately 5° increments. 1D spectra for the wild-type gH peptide were acquired with 64 scans, for the PA peptide 1,000 scans were collected, and for both wild-type gH and PA peptides spectra were obtained with 2,048 complex data points. The temperature dependence of every identifiable resonance was monitored.
The spectra were processed by using NMRPipe (8) and analyzed by using the NMRView program (18). All structural calculations were performed by using DYANA version 1.5 (14) and MOLMOL (21). Coupling constants were measured by using the XEASY computer program (1). The Karplus equation (19) was used to derive
angle constraints from the measured coupling constants. Distance constraints were derived from NOE cross-peak intensities within NMRView and corrected for pseudoatoms and methyl intensities within DYANA.
|
|
|---|
![]() View larger version (40K): [in a new window] |
FIG. 1. Coimmunoprecipitation of gH and VP16 from infected cells. Cell lysates were prepared from cells infected with HSV (wild type [WT]) or gH-null HSV (gH) or from uninfected cells (U). Lysates were incubated (+) or not incubated () with mouse anti-VP16 monoclonal antibody at 37°C. Total cell lysates (CL: lanes 1 to 3), immunoprecipitated (bound) material (lanes 4 to 8), and unbound material (lanes 9 to 13) were subjected to SDS-PAGE, Western blotted, and probed with anti-gH and anti-VP16 antisera as indicated at the left. Positions and masses (in kilodaltons) of molecular mass markers are indicated by arrows. Note that 1/10 the total unbound material was run on the gels.
|
110 kDa, corresponding to the molecular weight of gH. This band disappeared when anti-VP16 antibodies were omitted (Fig. 1, lane 5, lower panel) or when the infecting virus was a gH-null strain (lanes 6 and 7, lower panel). These data imply that full-length gH can be coimmunoprecipitated with VP16, suggesting the two polypeptides interact in infected cells, consistent with our findings (13) and earlier cross-linking studies (36). In control experiments, gC was found to not specifically coimmunoprecipitate with anti-VP16 antibodies, showing that gH is not recovered as part of a "bulk" incompletely solubilized envelope fraction. Nevertheless, we cannot discount the possibility that other envelope and tegument components may be specifically associated with the VP16/gH complex, and we are currently examining this possibility. Temperature dependence of VP16/gH interaction. In our previous studies we found that binding of gH to VP16 was temperature dependent -binding was detectable within 1 h when incubations were conducted at 37°C, but not at room temperature or 4°C (13). We wanted to test whether the in vivo binding of full-length gH and VP16 was similarly dependent on temperature. Figure 2 shows a series of immunoprecipitation reactions incubated at different temperatures with lysates from SC16-infected cells in the presence (lanes 2, 4, 6, 8, 10, and 12) or absence (lanes 3, 5, 7, 9, 11, and 13) of VP16 antibody. As with the previous experiment, material that was bound (Fig. 2, lanes 2 to 7) or unbound (lanes 8 to 13) to the beads, and the initial cell lysate (lane 1) were subjected to SDS-PAGE and Western blotted for VP16 and gH. Consistent with previous in vitro and in vivo findings, full-length gH only coimmunoprecipitated with VP16 at 37°C but not at room temperature or 4°C.
![]() View larger version (33K): [in a new window] |
FIG. 2. Temperature dependence of VP16/gH coimmunoprecipitation. Coimmunoprecipitation experiments were performed as described in the legend to Fig. 1, except that incubation was done at 37°C, room temperature (RT), or 4°C. Western blotting was performed with total cell lysates (CL: lane 1) as well as bound (lanes 2 to 7) and unbound (lanes 8 to 13) material as described in the legend to Fig. 1. Note that 1/10 the total unbound material was run on the gels.
|
As an alternative, we considered the possibility that the temperature dependence of binding might result from conformational changes in the gH tail. In this model, the conformation of gH at 37°C is compatible with VP16 binding, but at reduced temperatures the tail undergoes conformational changes which preclude its association with VP16. Since our previous studies have shown that mutation of the proline residue in the center of the tail permits VP16 binding even at 4°C (13), this hypothesis predicts that the mutant tail would be in the binding-permissive conformation at all temperatures. To test our hypothesis, we examined the structural properties of peptides corresponding to the cytoplasmic tails of wild-type gH and the PA mutant.
Conformation of gH C-terminal peptides. We used 1D and 2D NMR spectroscopy to characterize the temperature-dependent conformations of peptides corresponding to the C-terminal segments of wild-type (KVLRTSVPFFWRRE) and PA mutant gH (KVLRTSVAFFWRRE), beginning with the wild-type sequence at low temperature. 2D homonuclear DQF-COSY, TOCSY, and NOESY NMR spectra were used to assign the resonances of the peptide at 10°C. Figure 3A shows the fingerprint region of a 2D TOCSY spectrum. This experiment allows one to correlate, through scalar coupling, most or all of the protons in the spin system of a given residue. This region of the spectrum is particularly useful because the direct dimension represents the amide proton chemical shift, and the indirect dimension shows a set of cross-peaks to all other scalar-coupled protons in the side chain. One observes a single set of correlations for each amino acid except proline. Using these data, we were able to assign a residue type to each amide, and hence identify all the amino acid types in the peptide. A few cross-peaks in the TOCSY spectrum remained unassigned; these cross-peaks likely arise from contaminants from the peptide synthesis, and did not affect the analysis. A 2D DQF-COSY, which exclusively correlates protons on neighboring carbon or nitrogen nuclei via 3JH-H scalar coupling, was used to unambiguously assign all side chain protons, including those of Pro8 (the single proline in the tail, lying close to the center of the sequence) which do not appear in the fingerprint region of the TOCSY spectrum.
![]() View larger version (22K): [in a new window] |
FIG. 3. 2D NMR spectra of wild-type gH peptide. (A) 2D TOCSY spectrum highlighting the amide side-chain correlations. Assignments of residue and atom types are shown. (B) 1HN-1H region of the NOESY spectrum. The sequence-specific connections are indicated by red lines.
|
region of the NOESY spectrum. Each cross-peak occurs at either the chemical shift of the 1HNi-1H
i or the 1HNi-1H
I1, where i represents an amino acid residue in the sequence. The 1HN-1Hß chemical shifts of Thr5 and Ser6 are also seen in this region, but are not used in the assignment process. Connections between amino acids that are adjacent in sequence are indicated in Fig. 3B. Several resonances were overlapped, including Leu3 and Arg4, Val2 and Arg13, and Thr5, and Val7 and Phe9, but it was still possible to make connections between resonances, and hence the sequence-specific assignments.
Most observed NOEs were intraresidue or short-range between adjacent residues. However, a significant number of longer medium-range NOEs were observed in the central region of the peptide, between protons in residues 5 through 10 (Fig. 4). Figure 4A illustrates NOEs between residues 8 and 5 and residues 10 and 7, with additional NOEs between residues 10 and 7 and residues 9 and 7 visible in Fig. 4B and C. A total of 113 intraresidue, 47 interresidue, and 21 medium-range NOEs were used to derive distance constraints for structure calculations. 3JN
coupling constants were measured and used to define phi angle constraints for residues 2, 4 to 7, 9, and 11 to 14. For the structure calculation, these angles were loosely defined as falling in the range of 35° to 175°.
![]() View larger version (19K): [in a new window] |
FIG. 4. Expansions of the NOESY spectrum of wild-type gH peptide showing medium-range NOEs. The regions shown are NOEs between the side chains of Thr5 and Pro8 and of Val7 and Phe10 (A), the amide of Phe10 and the side chain of Val7 (B), and ring protons of Phe10 and the side chain of Val7 (C).
|
![]() View larger version (21K): [in a new window] |
FIG. 5. Structural model of wild-type gH tail peptide at 10°C. The nine lowest-energy structures are superimposed. Residues 1 to 3 and residues 11 to 14 are highly disordered and were omitted for clarity. The backbone is colored blue, and the side chains are colored red, with the exception of those of Val7, Pro8, and Phe10, which are highlighted in green.
|
![]() View larger version (49K): [in a new window] |
FIG. 6. Temperature dependence of aliphatic proton NMR resonances in wild-type and mutant gH peptides. (A) 1D 1H NMR spectra of wild-type (WT) gH peptide recorded from 2°C (bottom) to 45°C (top). The red lines indicate a significant change in chemical shift with temperature. (B) 1D 1H NMR spectra of gH PA mutant peptide recorded from 2 to 40°C. The red lines indicate little to no change in chemical shift with temperature. (C) Temperature profiles of three individual resonances (Arg4, Pro8, and Phe10, indicated in the single-letter amino acid code) of the wild-type gH peptide indicating cooperative changes with temperature.
|
|
|
|---|
The solution conformations of the gH peptide exhibited several interesting features. We first attempted to determine the structure at 37°C, but very few NOEs were observed in either NOESY or ROESY spectra, indicating that the peptide is dynamic and unstructured at this temperature. We were able to determine the structure at 10°C. A number of obvious medium-range NOEs were observed between protons of residues 5 through 10, including several between protons of Val7 and Phe10. These two residues are in close van der Waals contact in the resulting structural models. This results in a tight turn of the peptide backbone, facilitated by Pro8. There is also a distinct NOE between the
1 proton of Pro8 and the
proton of Thr5. The absence of a NOE involving the
2 proton suggests that the backbone is in a specific, stable structure. We propose that this small amount of stable structure is what inhibits binding to VP16 at temperatures lower that 37°C. At 37°C, the energy of thermal fluctuations is greater than the energy of the intramolecular interactions, and therefore the structure is destabilized. This is consistent with an induced fit mechanism in which the peptide must be unstructured in order to bind VP16. Any preformed structure inhibits binding.
This idea is supported by the fact that the PA mutant can bind at any temperature studied. A proline can restrict the conformation of a peptide. This in turn would reduce the conformational entropy contribution to the Gibbs free energy, hence allowing the enthalpy term to make a greater contribution. Thus, a few relatively weak interactions could result in the stabilization of a structure when a proline is present. Conversely, as in this situation, substitution of a proline with alanine increases the entropy and destabilizes the peptide structure. We attempted to determine the structure of the PA mutant at 10°C but were unsuccessful. The PA mutant is much less soluble than the wild-type peptide and yielded very weak NMR signals. Hence, we carried out a series of 1D 1H NMR experiments at temperatures varying from 2 to 40°C (Fig. 6). If one looks carefully at the wild-type peptide data, it is apparent that several resonances shift with temperature. Closer inspection reveals that the temperature profiles of individual resonances have a sigmoidal shape, typical of a cooperative denaturation curve. On the contrary, in the PA NMR spectrum, it is apparent that the resonances in the same spectral region have very little to no temperature dependence. This suggests that the mutant peptide does not contain the structure that is present in the wild-type peptide.
In summary, we have demonstrated that at 10°C a small segment of the gH peptide is structured. As the temperature is increased, this structure denatures. It is the loss of this structure that facilitates the peptide binding to VP16. The presence of the proline at position eight is a major contributor to the stability of this structure, and hence, if one mutates this proline to alanine, the structure is completely destabilized and the peptide binds freely at all temperatures.
The residues involved in the conformational transitions, as identified by sequential 1D NMR spectra, are remarkably consistent with the findings of our previous mutagenesis study (13). These residues include the leucine at position 3, the proline at position 8, the phenylalanine at position 10, the tryptophan at position 11, the glutamic acid residue at position 14, and to a more limited extent the arginine at position 13. These residues have all been shown to be involved in VP16 binding, either by promoting binding (Leu3, Phe10, Trp11, and Arg13) or by interfering with it (Pro8 and Glu14) (13).
It is becoming increasingly clear that HSV particle assembly is a process with a great deal of inherent redundancy (3, 11, 12, 26). The fact that the gH cytoplasmic tail must be unstructured in order to bind VP16 suggests one mechanism by which such redundancy may be achieved. We hypothesize that gH may bind VP16 via an "induced-fit" mechanism, wherein the tail must be malleable and unstructured before binding in order to assume a specific conformation upon interaction with VP16 but perhaps an alternative conformation when binding other tegument components. In this way, the gH tail can select from an array of possible binding partners, Such flexibility would maximize the efficiency with which viral structural components are assembled into the maturing particle.
Rabbit anti-gH antisera were generously provided by A. C. Minson. We thank Ruth Angeletti and Lisa Mints in the Laboratory for Macromolecular Analysis of the Albert Einstein College of Medicine for peptide synthesis and helpful advice.
D.E.K. and S.T.G. contributed equally to the work reported in this article. ![]()
|
|
|---|
deenvelopment
reenvelopment pathway. J. Virol. 75:5697-5702.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»